Tepnel Life Sciences (UK) reports reduced net loss:
This article was originally published in Clinica
Tepnel Life Sciences (UK) has reduced its loss to £890,000 ($1.4 million) in the half-year to the end of March from £1.01 million a year earlier. Anthony Martin, chairman since February, believes the company has sufficient financial resources to support its plans for the rest of 1995. Tepnel intends to concentrate on the introduction of its DNA technology in the genetic and cancer testing markets. The company says it is developing Solid Phase Amplification (SPA), a new method of DNA detection as an extension to its DARAS technology, for automated identification of DNA.